Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-02
2011-08-02
Thomas, Timothy P (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S452000
Reexamination Certificate
active
07989491
ABSTRACT:
In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infections by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting a squamous cell carcinoma, and methods of inhibiting the replication of a virus, by administering artemisinin-related compounds.
REFERENCES:
patent: 4978676 (1990-12-01), Thornfeldt
patent: 5219880 (1993-06-01), Thornfeldt
patent: 5225554 (1993-07-01), Avery et al.
patent: 5409938 (1995-04-01), Boyd et al.
patent: 5578637 (1996-11-01), Lai et al.
patent: 5639761 (1997-06-01), Francois et al.
patent: 5677468 (1997-10-01), Zheng et al.
patent: 5856351 (1999-01-01), Zheng et al.
patent: 6160004 (2000-12-01), Posner et al.
patent: 6297272 (2001-10-01), Posner et al.
patent: 2002/0169140 (2002-11-01), Prendergast
patent: 2004/0115651 (2004-06-01), Bennett et al.
patent: 0 428 773 (1991-05-01), None
patent: 0 713 877 (1996-05-01), None
patent: WO 01/42467 (2001-06-01), None
patent: WO-01/49242 (2001-07-01), None
patent: WO-02/24207 (2002-03-01), None
patent: WO 2004/041176 (2004-05-01), None
Garland; “Human papillomavirus update with a particular focus on cervical disease”; Jun. 2002; Pathology; 34(3): 213-224.
Long, et al.; “Prevention, Diagnosis, and Treatment of Cervical Cancer”; 2007; Mayo Clin. Proc.; 82(12); 1566-1574.
Opsenica et al.; “Cholic Acid Derivatives as 1,2,4,5-Tetraoxane Carriers: Structure and Antimalarial and Antiproliferative Activity”; 2000; J. Med. Chem.; 43: 3274-3282.
Beekman, et al., “Stability of artemisinin in aqueous environments: impact on its cytotoxic action to Ehrlich ascites tumour cells,” J Pharm Pharmacol, 49, 1254-1258 (1997).
De Clercq, “Molecular Targets for Antiviral Agents,” The Journal of Pharmacology and Experimental Therapeutics, 297(1), 1-10 (2001).
Efferth, et al., “Antiviral Activity of Artesunate Towards Wild-Type, Recombinant, and Ganciclovir-resistant human cytomegaloviruses”, Journal of Molecular Medicine (Berlin), 80(4), pp. 233-242, Apr. 2002.
Efferth, et al., “The anti-malarial artesunate is also active against cancer,” Int J Oncol, 18(4):767-73 (2001).
Moore, et al., “Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat,” Cancer Lett, 98, 83-87 (1995).
Posner, et al., “Antimalarial, anti-proliferative, and anti-tumor activities of artemisinin-derived, chemically robust, trioxane dimers,” J Med Chem, 42(21), 4275-80 (Oct. 21, 1999).
Singh, et al., “Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells,” Life Sci Nov. 21, 2001;70(1):49-56.
Sun, et al. “Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro,” Zhongguo Yao Li Xue Bao, 13(6):541-3 (1992), abstract only.
Database WPI Section Ch, Week 199730 Derwent Publications Ltd., London, GB; AN 1997-320247 XP002288323 & CN 1 105 238 A (Inst Virology China Acad Preventive Medi) (Jul. 19. 1995), abstract only.
Database WPI Section Ch, Week 199747 Derwent Publications Ltd., London, GB; AN 1997-503676 XP002288324 & CN 1 114 563 A (LI Z) (Jan. 10,1996), abstract only.
“Qingaosu (Artemisinin): An Antimalarial Drug from China” by Klayman, Science, vol. 228, May 31, 1985, pp. 1049-1055.
“Differential Toxicities of Anticancer Agents among DNA Repair and Checkpoint Mutants ofSaccharomyces cerevisiae” by Simon, et al., Cancer Research, 60, Jan. 15, 2000, pp. 328-333.
“Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro” by Chen, et al. Pharmacological Research, 48 (2003) 231-236.
“Dihydroartemisinin Is Cytotoxic to Papillomavirus-Expressing Epithelial Cells In vitro and In vivo” by Disbrow, et al., Cancer Research, 65: (23), Dec. 1, 2005, pp. 10854-10861.
“Psoriasis: A Possible Reservoir for Human Papillomavirus Type 5, the Virus Associated with Skin Carcinomas of Epidermodysplasia Verruciformis” by Favre, et al., J. Invest Dermatol 110:311-317, 1998.
“Detection of Human Papillomavirus DNA in PUVA-Associated Non-Melanoma Skin Cancers” by Harwood, et al., J Invest Dermatol 111:123-127, 1998.
Abstract—“Susceptibility locus for epidermodysplaisa verruciformis not linked to cervical cancer in situ” by Besko, et al., Hereditas. 2001;135(1):61-3.
“Human papillomavirus in cutaneous squamous cell carcinoma and cervix of a patient with psoriasis and extensive ultraviolet radiation exposure” by Rust, et al., J Am Acad Dermatol 2001;44:681-6.
“Do Epidermodysplasia Verruciformis Human Papillomaviruses Contribute to Malignant and Benign Epidermal Proliferations?” by Majewski, et al., Arch Dermatol. 2002;138:649-654.
“Chapter 9: Role of Mucosal Human Papillomavirus in Nongenital Cancers” by Gillison, et al., J Natl Cancer Inst Monogr 2003;31:57-65.
“Lower airway papillomatosis in children” by Zawadzka-Glos, et al., International Journal of Pediatric Otorhinolaryngology (2003) 67, 1117-1121.
“Classification of papillomaviruses” by de Villiers, et al., Virology 324 (2004) 17-27.
“Latent Human Papillomavirus Infection Is Comparable in the Larynx and Trachea” by Abramson, et al., Journal of Medical Virology 72:473-477 (2004).
“Pathogenesis of Human Papillomaviruses in Differentiating Epithelia” by Longworth, et al., Microbiology and Molecular Biology Reviews, vol. 68, No. 2, Jun. 2004, p. 362-372.
“Psoriasis: More Than Cosmetic” by Bren, FDA Consumer Magazine, Sep.-Oct. 2004 Issue, http://www.fda.gov/fdac/features/2004/504—psoriasis.html.
“Psoriasis and Immune System Involvement”, National Psoriasis Foundation, http://www.psoriasis.org/research/known/immune.php, Updated Jun. 2004.
“Increased Prevalence of Human Papillomavirus in Hairs Plucked From Patients With Psoriasis Treated With Psoralen-UV-A” by Wolf, et al., Arch Dermatol. 2004;140:317-324.
“The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses” by Bernard, Journal of Virology 32S (2005) S1-S6.
“Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review” by Kreimer, et al., Cancer Epidemiol Biomarkers Prev 2005;14(2), 467-475.
“Prevalence of human papillomavirus type 5 DNA in lesional and non-lesional skin scales of Italian plaque-type psoriatic patients: association with disease severity” by Prignano, et al., Clin Microbiol Infect 2005;11:47-51.
“Psoriasis” by Schon, et al., N Engl J Med 2005:352-1899-1912.
“Psoriasis Heath Center, 7 Psoriasis Triggers” Editedby Cynthia Dennison Haines, MC on Sep. 1, 2005, http://www.webmd.com/skin-problems-and-treatments/psoriais/7-psoriasis-triggers.
“Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer” by Munoz, et al., N Engl J Med 2003;348:518-527.
“Psoriasis: More than Cosmetic” by Bren, U.S. Food and Drug Administration, http://www.fda.gov/fdac/features/2004/504—psoriasis.html.
Medical Encyclopedia:Molluscum contagiosum, http://www.nlm.nih.gov/medlineplus/print/ency/article/000826.htm.
“Immunity and counter-immunity during infection with the parapoxvirus orf virus” by Haig, et al., Virus Research 88 (2002) 3-16.
“Virus Taxonomy” by Fauquet, et al., 8th Reports of the International Committee on Taxonomy of Viruses, Academic Press, 1162 pp. (2005) Elsevier, Publication Date: May 27, 2005.
Baege Astrid
Hartmann Dan-Paul
Schlegel Richard
Georgetown University
Morgan Lewis & Bockus LLP
Thomas Timothy P
LandOfFree
Use of artemisinin for treating tumors induced by oncogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of artemisinin for treating tumors induced by oncogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of artemisinin for treating tumors induced by oncogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2778363